Results 91 to 100 of about 30,431 (245)

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases. [PDF]

ACS Omega, 2022
Sanachai K, Mahalapbutr P, Hengphasatporn K, Shigeta Y, Seetaha S, Tabtimmai L, Langer T, Wolschann P, Kittikool T, Yotphan S, Choowongkomon K, Rungrotmongkol T.   +11 more
europepmc   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events. [PDF]

Front Immunol, 2023
Favalli EG, Cincinelli G, Germinario S, Di Taranto R, Orsini F, Maioli G, Biggioggero M, Ferrito M, Caporali R.   +8 more
europepmc   +1 more source

Nail Lichen Planus in Children ‐ Epidemiology, Pathogenesis, Clinical Presentation, and Treatment

JEADV Clinical Practice, EarlyView.
ABSTRACT Nail lichen planus (NLP) is a chronic inflammatory disorder that, while rare in children compared to adults, represents a significant cause of pediatric nail dystrophy that requires early recognition to prevent permanent scarring and nail loss.
Francesca Pampaloni, Matilde Iorizzo
wiley   +1 more source

Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model

Molecules
Allogeneic hematopoietic cell transplantation (allo-HCT) is a highly effective, well-established treatment for patients with various hematologic malignancies and non-malignant diseases.
Sena Kim, Peter Ruminski, Megh Singh, Karl Staser, Kidist Ashami, Julie Ritchey, Sora Lim, John F. DiPersio, Jaebok Choi   +8 more
doaj   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

LncRNA NORAD Enhances Inflammatory Injury in Sepsis‐Associated Acute Lung Damage Through miR‐150‐5p/STAT1‐Dependent NF‐κB Activation

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Acute lung injury (ALI) is a severe complication of sepsis, yet the role of lncRNA NORAD in its pathogenesis remains unclear. Using LPS‐stimulated BEAS‐2B and HBEC3‐KT cells as well as cecal ligation and puncture (CLP)‐induced ALI models in C57BL/6 mice, we found that NORAD expression was markedly upregulated and promoted cell injury ...
Han Liu, Xi‐Xi Chen, Gui‐Hua Wei, Feng Li, Hai‐Yan Zong   +4 more
wiley   +1 more source

Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics

MedComm – Oncology
Janus Kinases (JAKs) play a crucial role as therapeutic targets for various cancers. However, the current JAK inhibitors (JAKi) available have limited therapeutic benefits due to their lack of selectivity.
Tian‐Hua Wei, Meng‐Yi Lu, Si‐Hui Yao, Yu‐Qi Hong, Jin Yang, Meng‐Yuan Zhang, Yu‐Qi Yin, Yu‐Jie Han, Qing‐Qing Li, Zi‐Xuan Wang, Yi‐Bo Wang, Zhen‐Jiang Tong, Yun Zhou, Wei‐Chen Dai, Yan‐Cheng Yu, Shan‐Liang Sun, Ye Yang, Nian‐Guang Li, Zhi‐Hao Shi   +18 more
doaj   +1 more source